3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
55
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Neoplasms
1
Malignant Neoplasms of Female Genital Organs
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Neoplasms
1
HR-positive, HER2-negative Breast Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genital Neoplasms, Female
1
Genetic Diseases, Inborn
1
Estrogen Receptor Positive Breast Cancer
1
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
1
Disease Progression
1
Interventions
Radiotherapy
3
Radiation
3
palbociclib
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Doxorubicin
2
zimberelimab
1
talimogene laherparepvec
1
sotigalimab
1
ribociclib
1
pazopanib
1
eribulin
1
enzalutamide
1
durvalumab
1
cemiplimab
1
abemaciclib
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Nivolumab
1
Midazolam
1
Letrozole
1
Ipilimumab
1
Ifosfamide
1
Fulvestrant
1
Everolimus
1
Disulfides
1
CTLA-4 Antigen
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Liposarcoma
×
Fulvestrant
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled